PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Pieris Pharmaceuticals, Inc. (PIRS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US7207951036

CUSIP

720795103

Sector

Healthcare

IPO Date

Apr 13, 2015

Highlights

Market Cap

$21.14M

EPS (TTM)

-$12.11

Total Revenue (TTM)

$53.00K

Gross Profit (TTM)

-$668.00K

EBITDA (TTM)

-$12.62M

Year Range

$6.20 - $22.32

Target Price

$7.00

Short %

2.12%

Short Ratio

3.52

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Pieris Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%Aug 25SeptemberSep 08Sep 15Sep 22Sep 29Oct 06Oct 13Oct 20Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08
-33.76%
7.65%
PIRS (Pieris Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period


PIRS

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of PIRS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20241.59%-10.71%10.96%-20.10%-13.32%-3.34%69.20%10.84%-9.89%4.04%-5.77%-17.38%
202353.85%-6.25%-34.93%-22.58%12.22%-80.48%33.53%53.53%-12.17%-20.40%-13.87%-10.92%-82.50%
2022-3.70%-15.11%-1.94%-7.59%-36.43%5.06%-5.88%-17.05%-21.23%-3.48%-12.12%6.61%-72.49%
20211.60%7.09%-5.51%-15.95%59.26%11.34%-9.14%54.89%-4.08%-11.41%-27.95%14.55%51.20%
20202.21%-15.95%-26.69%16.23%35.85%-13.89%-17.10%11.28%-27.62%21.26%16.33%-14.38%-30.94%
20197.89%4.53%11.67%-10.75%38.46%13.53%17.02%-15.45%-26.67%-2.93%22.96%-11.06%36.09%
2018-0.26%13.15%-19.95%-6.60%-11.77%-9.79%8.28%0.91%1.08%-26.43%-17.72%-21.53%-64.77%
201755.85%-6.85%27.45%-7.31%90.04%10.48%2.77%5.96%4.54%-12.33%22.38%22.17%437.29%
2016-24.45%2.89%6.74%5.79%-5.47%-15.26%9.32%-9.09%14.22%-17.92%2.66%-8.75%-38.64%
2015-17.81%3.33%-11.29%16.36%-14.06%-33.46%-13.11%57.86%-8.76%-37.26%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PIRS is 65, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PIRS is 6565
Overall Rank
The Sharpe Ratio Rank of PIRS is 5757
Sharpe Ratio Rank
The Sortino Ratio Rank of PIRS is 7575
Sortino Ratio Rank
The Omega Ratio Rank of PIRS is 7272
Omega Ratio Rank
The Calmar Ratio Rank of PIRS is 6060
Calmar Ratio Rank
The Martin Ratio Rank of PIRS is 6060
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Pieris Pharmaceuticals, Inc. (PIRS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
PIRS
^GSPC

There is not enough data available to calculate the Sharpe ratio for Pieris Pharmaceuticals, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio0.001.002.003.00Aug 25SeptemberSep 08Sep 15Sep 22Sep 29Oct 06Oct 13Oct 20Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08
0.07
2.34
PIRS (Pieris Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Pieris Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Aug 25SeptemberSep 08Sep 15Sep 22Sep 29Oct 06Oct 13Oct 20Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08
-98.41%
-0.64%
PIRS (Pieris Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Pieris Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pieris Pharmaceuticals, Inc. was 99.14%, occurring on Jul 11, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.14%Feb 14, 20181611Jul 11, 2024
-67.74%Jun 24, 2015374Dec 14, 2016111May 25, 2017485
-29.33%Apr 20, 201513May 7, 201526Jun 19, 201539
-28.33%Oct 6, 201714Oct 25, 201742Dec 26, 201756
-24.05%Jul 12, 201723Aug 11, 201735Oct 2, 201758

Volatility

Volatility Chart

The current Pieris Pharmaceuticals, Inc. volatility is 33.52%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%Aug 25SeptemberSep 08Sep 15Sep 22Sep 29Oct 06Oct 13Oct 20Oct 27Nov 03Nov 10Nov 17Nov 24DecemberDec 08
33.52%
2.43%
PIRS (Pieris Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Pieris Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Pieris Pharmaceuticals, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab